CUE — Cue Biopharma Share News
0.000.00%
Last trade - 00:00- $102.72m
- $86.34m
- $27.47m
Cue Biopharma Q4 revenue surges on ImmunoScape deal
Brief: Cue Biopharma Appoints Industry Veteran Lucinda Warren As Chief Financial And Business Officer
Brief: Cue Biopharma Announces Pricing Of $10 Million Public Offering
Brief: Immunoscape Signs Deal With Cue Biopharma To Develop Solid Tumor Cancer Treatment
Cue Biopharma Q3 collaboration revenue falls
Brief: Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Brief: Cue Biopharma Appoints New CEO, Shifts Focus to Autoimmune Therapies
Cue Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cue Biopharma Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Cue Biopharma Updates on CUE-101 at DAVA 4th Hawaii Summit
Brief: Cue Biopharma CEO Daniel Passeri To Serve As Interim CFO
Cue Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Cue Biopharma Inc expected to post a loss of 15 cents a share - Earnings Preview
Cue Biopharma Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789
Brief: Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments
Cue Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary
Cue Biopharma Inc expected to post a loss of 16 cents a share - Earnings Preview
Cue Biopharma Inc expected to post a loss of 16 cents a share - Earnings Preview